No OS Benefit With Ibrutinib in Early-Stage, High-Risk CLL
Patients with early-stage, high-risk chronic lymphocytic leukemia (CLL) failed…
Browsing Tag
ibrutinib
Ibrutinib Highly Effective as First-Line Mantle Cell Lymphoma Treatment
Results of a large randomized trial support the inclusion of ibrutinib (Imbruvica) to the standard…
‘Practice-Changing’ Results With Zanubrutinib Versus Ibrutinib in CLL/SLL
NEW ORLEANS -- In patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL),…
Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma
NEW ORLEANS -- Results of a large randomized trial support the inclusion of ibrutinib (Imbruvica) to the standard first-line…
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination…
Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib are encouraging and continue to improve over prior reportingThe ORR of 89% and CR rate of 43% for…
Myeloma Risk in 9/11 Workers; New Ibrutinib Indication; Help for Chemo Brain?
More evidence that first responders and clean-up crews at the site of the World Trade Center…
Novel Ibrutinib Combo Shows High Response Rates in MCL, CLL
Patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) who were treated with…
ASCO: Add-On Ibrutinib Slows Mantle-Cell Lymphoma in Older Adults
Physician’s Briefing Staff
FRIDAY, June 3, 2022 (HealthDay News) -- For older patients with untreated mantle-cell lymphoma, the addition of ibrutinib to…
Ibrutinib with chemoimmunotherapy improved progression-free survival for newly…
Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously…
Add-On Ibrutinib Boosts PFS in Untreated, Older Mantle-Cell Lymphoma Patients
CHICAGO -- A combination of chemoimmunotherapy plus ibrutinib (Imbruvica) significantly reduced the risk of disease progression or…